Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:ERAS NASDAQ:PTGX NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$153.35-0.7%$167.45$56.10▼$200.00$6.13B-1.19185,140 shs78,756 shsERASErasca$10.70+7.1%$15.79$1.06▼$24.28$3.34B0.687.28 million shs1.79 million shsPTGXProtagonist Therapeutics$102.39+3.2%$98.82$41.28▼$107.84$6.58B1.89767,394 shs193,347 shsVIRVir Biotechnology$10.21+2.0%$9.56$4.16▼$11.66$1.65B1.73.02 million shs388,871 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio-0.30%-2.74%-9.11%-15.54%+147.01%ERASErasca-0.40%+0.91%-43.91%-11.12%+588.97%PTGXProtagonist Therapeutics+0.85%-1.98%-4.40%+19.10%+124.05%VIRVir Biotechnology+0.10%-2.63%+10.49%+33.47%+62.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$153.35-0.7%$167.45$56.10▼$200.00$6.13B-1.19185,140 shs78,756 shsERASErasca$10.70+7.1%$15.79$1.06▼$24.28$3.34B0.687.28 million shs1.79 million shsPTGXProtagonist Therapeutics$102.39+3.2%$98.82$41.28▼$107.84$6.58B1.89767,394 shs193,347 shsVIRVir Biotechnology$10.21+2.0%$9.56$4.16▼$11.66$1.65B1.73.02 million shs388,871 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio-0.30%-2.74%-9.11%-15.54%+147.01%ERASErasca-0.40%+0.91%-43.91%-11.12%+588.97%PTGXProtagonist Therapeutics+0.85%-1.98%-4.40%+19.10%+124.05%VIRVir Biotechnology+0.10%-2.63%+10.49%+33.47%+62.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 2.63Moderate Buy$202.3331.94% UpsideERASErasca 2.50Moderate Buy$17.8867.02% UpsidePTGXProtagonist Therapeutics 2.80Moderate Buy$113.6911.04% UpsideVIRVir Biotechnology 2.89Moderate Buy$20.3899.56% UpsideCurrent Analyst Ratings BreakdownLatest VIR, ERAS, BLTE, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.004/27/2026ERASErasca Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $30.004/22/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.004/14/2026PTGXProtagonist Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $121.004/13/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.004/10/2026VIRVir Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026BLTEBelite Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/19/2026PTGXProtagonist Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$107.00 ➝ $110.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$20.54 per shareN/AERASErascaN/AN/AN/AN/A$1.05 per shareN/APTGXProtagonist Therapeutics$46.02M143.08N/AN/A$9.83 per share10.42VIRVir Biotechnology$68.56M24.01N/AN/A$5.50 per share1.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$77.61M-$2.30N/AN/AN/AN/A-19.49%-19.05%5/12/2026 (Estimated)ERASErasca-$124.55M-$0.44N/AN/AN/AN/A-34.48%-28.74%5/12/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$2.05N/AN/AN/A-282.83%-19.89%-18.40%5/6/2026 (Estimated)VIRVir Biotechnology-$437.99M-$3.16N/AN/AN/A-638.88%-49.31%-38.74%5/6/2026 (Estimated)Latest VIR, ERAS, BLTE, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026BLTEBelite Bio-$0.60N/AN/AN/AN/AN/A5/12/2026Q1 2026ERASErasca-$0.19N/AN/AN/AN/AN/A5/6/2026Q1 2026PTGXProtagonist Therapeutics-$0.65$0.05+$0.70$0.05$12.21 million$56.37 million5/6/2026Q1 2026VIRVir Biotechnology-$0.01N/AN/AN/A$55.49 millionN/A3/12/2026Q4 2025ERASErasca-$0.11-$0.10+$0.01-$0.10N/AN/A3/2/2026Q4 2025BLTEBelite Bio-$0.56-$0.38+$0.18-$0.70N/AN/A2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 million2/23/2026Q4 2025VIRVir Biotechnology-$0.42-$0.31+$0.11-$0.31$19.91 million$64.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A50.0250.02ERASErascaN/A10.0410.04PTGXProtagonist TherapeuticsN/A12.7112.71VIRVir BiotechnologyN/A5.545.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%ERASErasca67.78%PTGXProtagonist Therapeutics98.63%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%ERASErasca14.40%PTGXProtagonist Therapeutics4.90%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1039.97 million34.65 millionNot OptionableERASErasca120310.97 million266.19 millionOptionablePTGXProtagonist Therapeutics12064.31 million61.15 millionOptionableVIRVir Biotechnology580161.23 million135.44 millionOptionableVIR, ERAS, BLTE, and PTGX HeadlinesRecent News About These CompaniesVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare ConferenceMay 5 at 4:05 PM | businesswire.comVir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares of StockMay 5 at 4:57 AM | americanbankingnews.comVicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) StockMay 5 at 4:52 AM | insidertrades.comVir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 SharesMay 4 at 2:51 PM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 3 at 4:19 AM | marketbeat.comWhy Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii ArbitrationApril 29, 2026 | finance.yahoo.comVir Biotechnology (VIR) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?April 27, 2026 | finance.yahoo.comVir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsApril 23, 2026 | businesswire.comVir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study UpdateApril 23, 2026 | tipranks.com10 Best Small-Cap Biotech Stocks According to Hedge FundsApril 21, 2026 | insidermonkey.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - Here's WhyApril 20, 2026 | marketbeat.comCan Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?April 20, 2026 | insidermonkey.comIs Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?April 19, 2026 | finance.yahoo.comVir Biotechnology, Inc. ($VIR) CEO 2025 Pay RevealedApril 16, 2026 | quiverquant.comQVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate CancerApril 16, 2026 | businesswire.comVir Biotechnology Rings the Closing BellApril 14, 2026 | nasdaq.comA Look At Vir Biotechnology (VIR) Valuation After New VIR-5500 Prostate Cancer Trial MilestoneApril 14, 2026 | finance.yahoo.comVir Biotechnology doses first patient in Phase I VIR-5500 trialApril 14, 2026 | yahoo.comVir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with ...April 13, 2026 | finance.yahoo.comFirst Patient Dosed in VIR-5500 T-Cell Engager Trial in Metastatic Prostate CancerApril 13, 2026 | targetedonc.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026Pipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026TPG Built a Record Year, Then Lost 40%—Is the Selloff Overdone? By Peter Frank | April 16, 2026Alcoa Dips After Q1 Miss, But Higher Aluminum Prices LoomBy Thomas Hughes | April 18, 2026The Volatility Harvester That Thrives in Market ChaosBy Peter Frank | April 27, 2026VIR, ERAS, BLTE, and PTGX Company DescriptionsBelite Bio NASDAQ:BLTE$153.35 -1.03 (-0.67%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Erasca NASDAQ:ERAS$10.70 +0.71 (+7.13%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Protagonist Therapeutics NASDAQ:PTGX$102.38 +3.18 (+3.20%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Vir Biotechnology NASDAQ:VIR$10.21 +0.20 (+2.00%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
